IPP Bureau
Medherant announces positive Phase 1 results of clinical trial of testosterone patch for women
By IPP Bureau - October 29, 2025
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Orion secures license to Abzena’s next-generation cancer antibody
By IPP Bureau - October 29, 2025
The antibody was designed and developed at Abzena’s Cambridge, UK,
Novartis completes acquisition of Tourmaline Bio
By IPP Bureau - October 29, 2025
Tourmaline is now an indirect wholly owned subsidiary of Novartis
FDA approves Alembic's Ticagrelor Tablets, 60 mg
By IPP Bureau - October 29, 2025
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Sai Life Sciences to double process R&D capacity with new facility in Hyderabad
By IPP Bureau - October 28, 2025
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Sanofi India appoints Deepak Arora as MD
By IPP Bureau - October 28, 2025
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
MilliporeSigma partners with Promega to advance 3-D cell drug discovery technologies
By IPP Bureau - October 28, 2025
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Akums breaks ground for its first overseas manufacturing facility in Zambia
By IPP Bureau - October 28, 2025
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Sigachi Industries posts Q2 FY2026 consolidated profit at Rs. 10.68 Cr
By IPP Bureau - October 27, 2025
Sigachi Industries has reported total income of Rs. 112.97 crore during the period ended September 30, 2025
Zydus receives approval from Health Canada for Mesalamine suppositories
By IPP Bureau - October 27, 2025
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Dr Reddys Laboratories reports Q2 FY26 consolidated PAT at Rs. 1,437.2 Cr
By IPP Bureau - October 27, 2025
Dr Reddys Laboratories has reported total income of Rs. 8,805.1 crore during the period ended September 30, 2025
Health Minister Nadda addresses 50th convocation of AIIMS New Delhi
By IPP Bureau - October 27, 2025
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
ANRF, in collaboration with ICMR and Gates Foundation, launches Maha MedTech Mission
By IPP Bureau - October 27, 2025
With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market
CPHI & PMEC India 2025 to see participation of 2,000+ exhibitors
By IPP Bureau - October 27, 2025
The event will be attended by 35,000+ industry professionals
Novartis to acquire Avidity Biosciences for $12 billion
By IPP Bureau - October 27, 2025
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
